Figure 5.
Treatment outcomes of Black and White AYA patients with respect to cytogenetic findings. DFS (A) and OS (B) of all Black and White AYA patients diagnosed with CBF-AML. DFS (C) and OS (D) of Black and White patients with AML aged 18 to 29 years and those aged 30 to 39 years who harbored inv(16)/t(16;16). Two Black patients with inv(16) aged 30 to 39 years are not included in the DFS plot. DFS (E) and OS (F) of patients aged 18 to 29 years with CBF-AML and of those with non–CBF-AML.

Treatment outcomes of Black and White AYA patients with respect to cytogenetic findings. DFS (A) and OS (B) of all Black and White AYA patients diagnosed with CBF-AML. DFS (C) and OS (D) of Black and White patients with AML aged 18 to 29 years and those aged 30 to 39 years who harbored inv(16)/t(16;16). Two Black patients with inv(16) aged 30 to 39 years are not included in the DFS plot. DFS (E) and OS (F) of patients aged 18 to 29 years with CBF-AML and of those with non–CBF-AML.

Close Modal

or Create an Account

Close Modal
Close Modal